A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Description of the Business and Background LivaNova PLC is a market-leading global medical technology company. The Company designs, develops, manufactures, markets, and sells products, therapies, and services that are consistent with LivaNova’s mission to “create ingenious medical solutions that ignite patient turnarounds.” LivaNova is a public limited company organized under the laws of England and Wales and is headquartered in London, England. LivaNova’s ordinary shares are listed for trading on the Nasdaq under the symbol “LIVN.” Business Overview LivaNova identifies operating segments based on how it manages, evaluates, and internally reports its business activities to allocate resources, develop and execute its strategy, and assess performance. LivaNova has two reportable segments: Cardiopulmonary and Neuromodulation. “Other” includes non-allocated corporate expenses and the non-cannula results of the Company’s former ACS segment, which was wound down during 2024.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 1.4B | 1.4B | 1.3B | 1.2B | 1.0B | 1.0B |
| Net Income | -242M | -242M | 63M | 18M | -86M | -136M |
| EPS | $-4.45 | $-4.45 | $1.16 | $0.32 | $-1.61 | $-2.68 |
| Free Cash Flow | 173M | 173M | 136M | 40M | 43M | 77M |
| ROIC | 15.8% | 15.8% | 5.8% | 1.0% | -5.7% | - |
| Gross Margin | 67.7% | 67.7% | 68.1% | 65.5% | 69.2% | 68.2% |
| Debt/Equity | 0.36 | 0.36 | 0.51 | 0.50 | 0.48 | 0.22 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 199M | 199M | 129M | -68M | -77M | - |
| Operating Margin | 14.4% | 14.4% | 10.3% | -5.9% | -7.5% | - |
| ROE | -20.2% | -19.2% | 4.9% | 1.4% | -6.9% | -11.3% |
| Shares Outstanding | 54M | 54M | 55M | 55M | 54M | 51M |
LivaNova PLC passes 4 of 9 quality checks, suggesting mixed fundamentals.
On a free-cash-flow basis, the stock trades at 20.4x vs a median of 57.7x. The company's 5-year average ROIC is 4.2% with a gross margin of 67.7%. At current prices, the estimated annualized return to fair value is +4.2%.
LivaNova PLC (LIVN) has a 5-year average return on invested capital (ROIC) of 4.2%. This is below average and may indicate limited pricing power.
LivaNova PLC (LIVN) has a market capitalization of $3.5B. It is classified as a mid-cap stock.
LivaNova PLC (LIVN) does not currently pay a regular dividend.
LivaNova PLC (LIVN) operates in the Electromedical & Electrotherapeutic Apparatus industry, within the Healthcare sector.
LivaNova PLC (LIVN) reported annual revenue of $1.4 billion in its most recent fiscal year, based on SEC EDGAR filings.
LivaNova PLC (LIVN) has a net profit margin of -17.5%. The company is currently unprofitable.
LivaNova PLC (LIVN) generated $173 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
LivaNova PLC (LIVN) has a debt-to-equity ratio of 0.36. This indicates a conservatively financed balance sheet.
LivaNova PLC (LIVN) reported earnings per share (EPS) of $-4.45 in its most recent fiscal year.
LivaNova PLC (LIVN) has a return on equity (ROE) of -19.2%. A negative ROE may indicate losses or negative equity.
LivaNova PLC (LIVN) has a 5-year average gross margin of 67.7%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 12 years of financial data for LivaNova PLC (LIVN), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
LivaNova PLC (LIVN) has a book value per share of $22.02, based on its most recent annual SEC filing.